Ignite Creation Date:
2025-12-24 @ 11:59 AM
Ignite Modification Date:
2026-04-15 @ 4:44 PM
Study NCT ID:
NCT01142661
Status:
COMPLETED
Last Update Posted:
2013-09-20
First Post:
2010-06-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Compassionate Use of Eribulin for the Treatment of Advanced Breast Cancer Refractory to All Other Marketed Therapies
Sponsor:
Eisai Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
E7389-G000-399
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None